A high-affinity native human antibody disrupts biofilm from Staphylococcus aureus bacteria and potentiates antibiotic efficacy in a mouse implant infection model

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2292-2301

  Estellés, Angeles ^a   Woischnig, Anne Kathrin ^b   Liu, Keyi ^a   Stephenson, Robert ^a   Lomongsod, Evelene ^a   Nguyen, Da ^a   Zhang, Jianzhong ^a   Heidecker, Manfred ^a   Yang, Yifan ^a   Simon, Reyna J ^a   Tenorio, Edgar ^a   Ellsworth, Stote ^a   Leighton, Anton ^a   Ryser, Stefan ^a   Gremmelmaier, Nina Khanna ^b   Kauvar, Lawrence M ^a  

^a Trellis Bioscience   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; HU PROTEIN; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY TRL1068; INTEGRATION HOST FACTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; DNA BINDING PROTEIN; HBSU PROTEIN, BACTERIA; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIOPLANKTON; BACTERIUM ADHERENCE; BIOFILM; CONTROLLED STUDY; DEVICE INFECTION; DRUG DNA BINDING; DRUG EFFICACY; DRUG POTENTIATION; DRUG SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REBOUND; SERUM; SINGLE DRUG DOSE; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; B LYMPHOCYTE; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; COMBINATION DRUG THERAPY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; EPITOPE MAPPING; FOREIGN BODIES; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MOLECULAR MODEL; PLANKTON; SEQUENCE ALIGNMENT; SINGLE CELL ANALYSIS; STAPHYLOCOCCAL INFECTIONS;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; BACTERIAL PROTEINS; BIOFILMS; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG THERAPY, COMBINATION; EPITOPE MAPPING; FEMALE; FOREIGN BODIES; GENE EXPRESSION; INJECTIONS, INTRAPERITONEAL; INTEGRATION HOST FACTORS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; PLANKTON; SEQUENCE ALIGNMENT; SINGLE-CELL ANALYSIS; STAPHYLOCOCCAL INFECTIONS;

EID: 84963770753     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02588-15     Document Type: Article

References (31)

1. Bjarnsholt T. 2013. The role of bacterial biofilms in chronic infections. APMIS Suppl 2013:1-51. http://dx.doi.org/10.1111/apm.12099.
2. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167-193. http://dx.doi.org/10.1128/CMR.15.2.167-193.2002.
3. Hall-Stoodley L, Stoodley P. 2009. Evolving concepts in biofilm infections. Cell Microbiol 11:1034-1043. http://dx.doi.org/10.1111/j.1462-5822.2009.01323.x.
4. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities ofbacterial biofilms. J Clin Microbiol 37:1771-1776.
5. Coenye T, Nelis HJ. 2010. In vitro and in vivo model systems to study microbial biofilm formation. J Microbiol Methods 83:89-105. http://dx.doi.org/10.1016/j.mimet.2010.08.018.
6. Lebeaux D, Chauhan A, Rendueles O, Beloin C. 2013. From in vitro to in vivo models of bacterial biofilm-related infections. Pathogens 2:288-356. http://dx.doi.org/10.3390/pathogens2020288.
7. Boles BR, Horswill AR. 2011. Staphylococcal biofilm disassembly. Trends Microbiol 19:449-455. http://dx.doi.org/10.1016/j.tim.2011.06.004.
8. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2:95-108. http://dx.doi.org/10.1038/nrmicro821.
9. Brady RA, Leid JG, Camper AK, Costerton JW, Shirtliff ME. 2006. Identification of Staphylococcus aureus proteins recognized by the antibody-mediated immune response to a biofilm infection. Infect Immun 74:3415-3426. http://dx.doi.org/10.1128/IAI.00392-06.
10. Joo HS, Otto M. 2012. Molecular basis of in vivo biofilm formation by bacterial pathogens. Chem Biol 19:1503-1513. http://dx.doi.org/10.1016/j.chembiol.2012.10.022.
11. Mann EE, Rice KC, Boles BR, Endres JL, Ranjit D, Chandramohan L, Tsang LH, Smeltzer MS, Horswill AR, Bayles KW. 2009. Modulation of eDNA release and degradation affects Staphylococcus aureus biofilm maturation. PLoS One 4:e5822. http://dx.doi.org/10.1371/journal.pone.0005822.
12. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. 2002. Extracellular DNA required for bacterial biofilm formation. Science 295:1487. http://dx.doi.org/10.1126/science.295.5559.1487.
13. Shields RC, Mokhtar N, Ford M, Hall MJ, Burgess JG, El Badawey MR, Jakubovics NS. 2013. Efficacy of a marine bacterial nuclease against biofilm forming microorganisms isolated from chronic rhinosinusitis. PLoS One 8:e55339. http://dx.doi.org/10.1371/journal.pone.0055339.
14. Goodman SD, Obergfell KP, Jurcisek JA, Novotny LA, Downey JS, Ayala EA, Tjokro N, Li B, Justice SS, Bakaletz LO. 2011. Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins. Mucosal Immunol 4:625-637. http://dx.doi.org/10.1038/mi.2011.27.
15. Khrapunov S, Brenowitz M, Rice PA, Catalano CE. 2006. Binding then bending: a mechanism for wrapping DNA. Proc Natl Acad Sci U S A 103:19217-19218. http://dx.doi.org/10.1073/pnas.0609223103.
16. Brockson ME, Novotny LA, Mokrzan EM, Malhotra S, Jurcisek JA, Akbar R, Devaraj A, Goodman SD, Bakaletz LO. 2014. Evaluation of the kinetics and mechanismofactionofanti-integration host factor-mediated disruption of bacterial biofilms. Mol Microbiol 93:1246-1258. http://dx.doi.org/10.1111/mmi.12735.
17. Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, Tripp RA, Walsh EE, Keyt BA, Kauvar LM. 2009. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 183:6338-6345. http://dx.doi.org/10.4049/jimmunol.0901373.
18. Harriman WD, Collarini EJ, Sperinde GV, Strandh M, Fatholahi MM, Dutta A, Lee Y, Mettler SE, Keyt BA, Ellsworth SL, Kauvar LM. 2009. Antibody discovery via multiplexed single cell characterization. J Immunol Methods 341:135-145. http://dx.doi.org/10.1016/j.jim.2008.11.009.
19. Durocher Y, Perret S, Kamen A. 2002. High-level and high-throughput recombinant protein production by transient transfection of suspensiongrowing human 293-EBNA1 cells. Nucleic Acids Res 30:E9. http://dx.doi.org/10.1093/nar/30.2.e9.
20. Lutz HU, Stammler P, Fischer EA. 1990. Covalent binding of detergent-solubilized membrane glycoproteins to "Chemobond" plates for ELISA. J Immunol Methods 129:211-220. http://dx.doi.org/10.1016/0022-1759 (90) 90441-W.
21. Harrison JJ, Stremick CA, Turner RJ, Allan ND, Olson ME, Ceri H. 2010. Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening. Nat Protoc 5:1236-1254. http://dx.doi.org/10.1038/nprot.2010.71.
22. Nowakowska J, Landmann R, Khanna N. 2014. Foreign body infection models to study host-pathogen response and antimicrobial tolerance of bacterial biofilm. Antibiotics 3:378. http://dx.doi.org/10.3390/antibiotics3030378.
23. John AK, Schmaler M, Khanna N, Landmann R. 2011. Reversible daptomycin tolerance of adherent staphylococci in an implant infection model. Antimicrob Agents Chemother 55:3510-3516. http://dx.doi.org/10.1128/AAC.00172-11.
24. Kim Do H, Im H, Jee JG, Jang SB, Yoon HJ, Kwon AR, Kang SM, Lee BJ. 2014. Beta-arm flexibility of HU from Staphylococcus aureus dictates the DNA-binding and recognition mechanism. Acta Crystallogr D Biol Crystallogr 70:3273-3289. http://dx.doi.org/10.1107/S139900471402 3931.
25. Fedorov O, Niesen FH, Knapp S. 2012. Kinase inhibitor selectivity profiling using differential scanning fluorimetry. Methods Mol Biol 795:109-118. http://dx.doi.org/10.1007/978-1-61779-337-0-7.
26. Dominguez-Herrera J, Docobo-Perez F, Lopez-Rojas R, Pichardo C, Ruiz-Valderas R, Lepe JA, Pachon J. 2012. Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 56:613-617. http://dx.doi.org/10.1128/AAC.05606-11.
27. Zimmerli W, Lew PD, Waldvogel FA. 1984. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Investig 73:1191-1200.
28. Darouiche RO. 2004. Treatment of infections associated with surgical implants. N Engl J Med 350:1422-1429. http://dx.doi.org/10.1056/NEJMra035415.
29. Tsaras G, Osmon DR, Mabry T, Lahr B, St Sauveur J, Yawn B, Kurland R, Berbari EF. 2012. Incidence, secular trends, and outcomes of prosthetic joint infection: a population-based study, Olmsted county, Minnesota, 1969-2007. Infect Control Hosp Epidemiol 33:1207-1212. http://dx.doi.org/10.1086/668421.
30. Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. 1982. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis 146:487-497. http://dx.doi.org/10.1093/infdis/146.4.487.
31. Kristian SA, Lauth X, Nizet V, Goetz F, Neumeister B, Peschel A, Landmann R. 2003. Alanylation of teichoic acids protects Staphylococcus aureus against Toll-like receptor 2-dependent host defense in a mouse tissue cage infection model. J Infect Dis 188:414-423. http://dx.doi.org/10.1086/376533.